New MRI-Guided radiation trial aims to outsmart aggressive brain tumors
NCT ID NCT07457307
First seen Mar 20, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This early-stage trial tests whether using a special MRI-guided radiation machine (MR-Linac) can safely deliver higher, more targeted radiation doses to aggressive brain tumors (high-grade glioma). Twenty newly diagnosed patients will receive radiation twice a week for three weeks along with daily temozolomide chemotherapy. The main goal is to check for severe side effects, not yet to prove the treatment works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Temozolomide (chemotherapy) and MR-Linac guided radiation therapy
What this could lead to
If successful, this could point toward a more precise, safer way to deliver higher doses of radiation for glioblastoma, potentially improving tumor control.
What could go wrong
This is a very early Phase 1 safety study with only 20 participants. It is not designed to prove effectiveness, and the approach may not improve survival or could cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.